🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "significant breakthrough" in the battle against increasingly resistant strains of the infection, according to scientists.

An International Public Health Issue

The sexually transmitted infection are increasing worldwide, with estimates suggesting over 82 million new cases each year. Particularly high rates are reported in Africa and countries within the WHO's designated area, which spans from China and Mongolia to New Zealand. In England, cases have reached a record high, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune advancement in the face of growing infection rates, the spread of superbugs and the highly restricted therapeutic options presently on offer.”

Health officials are increasingly worried about the rise in drug-resistant strains. The global health body has designated it as a "critical concern". A tracking program found that the effectiveness of key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Treatment Options Secure Approval

One new antibiotic, marketed under the name a brand name, was cleared by the American regulatory agency in mid-December for combating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Scientists anticipate that targeted use of this new drug will help slow the emergence of superbugs.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, gained clearance in concurrent days. This treatment, which is also used to treat UTIs, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin stemmed from a unique collaborative effort for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to develop it.

“This authorization signifies a huge turning point in the therapy of superbug gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Clinical Trial Data and Worldwide Availability

Based on results published in a major medical journal, the new drug cured more than 90% of cases of the STI. This places it at an comparable level with the typical regimen, which involves a dual-drug approach. The research included hundreds of participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the ability to make available and distribute the drug in a wide range of low-income and middle-income countries.

Doctors directly involved have shared positive views. Having a one-pill regimen of this kind is hailed as a "revolutionary step" for gonorrhoea control. This is deemed vital to alleviate the strain of the illness for individuals and to prevent the spread of highly drug-resistant gonorrhoea around the world.